EMA Updates On Brexit Progress With ‘At-Risk’ Drugs And Staffing Issues
Executive Summary
The European Medicines Agency has given an update on its Brexit preparations, including progress with dealing with “at-risk” medicines, staff retention and recruitment issues, and the resumption of some activities that have been temporarily shelved or cut back.
You may also be interested in...
EMA Set For More Staff Losses & Activity Cuts Next Year
The latest EMA management board meeting heard an update on the situation regarding Brexit-related staff losses and recruitment, and was told that an additional set of temporary suspensions or reductions in its activities might be necessary from the beginning of 2019.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.